Impax to Report Fourth Quarter and Full Year 2017 Results on March 1, 2018

HAYWARD, Calif., Jan. 16, 2018 /PRNewswire/ -- Impax Laboratories, Inc. (NASDAQ: IPXL) announced today that the Company will release its fourth quarter and full year 2017 financial results on Thursday, March 1, 2018, prior to the open of the U.S. financial markets. The Company will host a conference call and live webcast with the investment community at 8:30 a.m., Eastern Time on March 1, 2018. 

The financial results and live webcast will be accessible through the Investor Relations section of the Company's Web site at http://investors.impaxlabs.com.

To access the call through a conference line, dial (877) 356-3814 (in the U.S.) and (706) 758-0033 (international callers). The conference ID is 7677287.

A replay of the conference call will be available for seven days shortly after the call. To access the replay, dial (855) 859-2056 (in the U.S.) and (404) 537-3406 (international callers). The access code for the replay is 7677287.

About Impax Laboratories, Inc.
Impax Laboratories, Inc. (Impax) is a specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of central nervous system disorder branded products. Impax markets its generic products through its Impax Generics division and markets its branded products through the Impax Specialty Pharma division. Additionally, where strategically appropriate, Impax develops marketing partnerships to fully leverage its technology platform and pursues partnership opportunities that offer alternative dosage form technologies, such as injectables, nasal sprays, inhalers, patches, creams, and ointments.

For more information, visit Impax's website at: www.impaxlabs.com.

Contact:
Mark Donohue
Investor Relations and Corporate Communications 
(215) 558-4526                                                       
www.impaxlabs.com                                              

SOURCE Impax Laboratories, Inc.